1. Ansell J . Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost (2007) 5(Suppl.1):60–64.
2. Herbert JM , Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, Zandberg P, van Amsterdam RGM, van Boeckel CAA, Meuleman DG. SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev (1997) 15:1–26.
3. Savi P , Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood (2005) 105:139–144.
4. Donat F , Duret JP, Santoni A, Cariou R, Necciari J, Magnani H, de Greef R. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet (2002) 41(Suppl.2):1–9.
5. Lieu C , Shi J, Donat F, Van Horn R, Brian W, Newton J, Delbressine L, Vos R. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet (2002) 41(Suppl.2):19–26.